Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Acorda down 12% on Goldman cut in premarket analyst action

Published 12/11/2018, 08:58 AM
Updated 12/11/2018, 08:58 AM
© Reuters. Acorda down 12% on Goldman cut in premarket analyst action
  • Novavax (NASDAQ:NVAX) initiated with Outperform rating and $4 (87% upside) price target at Oppenheimer. Shares up 3% premarket.
  • Synthetic Biologics (NYSEMKT:SYN) initiated with Buy rating at Alliance Global Partners.
  • BioTime (NYSEMKT:BTX) resumed with Outperform rating and $3.50 (169% upside) price target at Oppenheimer. Shares up 2% premarket.
  • CVS Health (NYSE:CVS) resumed with Outperform rating and $100 price target at Leerink Partners. Shares up 2% premarket.
  • Medical Properties (NYSE:MPW) upgraded to Market Perform at Wells Fargo (NYSE:WFC). Shares up 1% premarket.
  • Acorda Therapeutics (NASDAQ:ACOR) downgraded to Sell with a $10 (47% downside risk) price target citing limited market opportunities for Parkinson's med Inbrija (levodopa inhalation powder). Shares down 12% premarket.
  • Pfizer (NYSE:PFE) downgraded to Neutral with a $46 (4% upside) price target at JPMorgan (NYSE:JPM). Shares down 1% premarket.
  • Quidel (NASDAQ:QDEL) downgraded to Hold with a $51 price target at Craig-Hallum.
  • Vanda Pharmaceuticals (NASDAQ:VNDA) downgraded to Market Perform with a $29 (flat) price target at Oppenheimer. Shares down 3% premarket.
  • Now read: Pfizer Wants To Get On Top In The NASH Space With The Combination Approach


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.